Susu has secured growth financing led by INCO Ventures to enhance its healthcare services in Africa's expanding market, targeting vulnerable populations with innovative insurance solutions.
Target Information
Susu is a Franco-African startup established in 2019 that specializes in delivering innovative and affordable healthcare and insurance solutions across Africa. With a rapidly growing population projected to reach 2 billion by 2050, Africa faces rising life expectancy rates alongside increasing instances of chronic conditions such as diabetes and hypertension. Susu aims to address these challenges by offering insurance products and tailored healthcare packages designed for various demographics, including seniors, individuals with chronic illnesses, and pregnant women.
The company's solutions encompass a digital platform that connects users to a wide-ranging medical network, promoting accessibility and quality healthcare. By leveraging unique financing strategies that tap into the African diaspora, Susu is well-positioned to serve both healthy individuals and vulnerable populations in need of health and insurance services.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Africa
The healthcare industry in Africa is undergoing significant transformation as the continent grapples with diverse health challenges amidst rapid demographic changes. With a youthful population, the demand for modern healthcare solut
Similar Deals
Codexial, Finovam Gestion, Groupe ILP, Angels Santé, Alsace Business Angels → StemInov
2026
Broadview Ventures and Advent Life Sciences → Relief Cardiovascular
2025
Capagro, Hoxton Ventures, CapHorn, Demeter, Acurio Ventures, Citizen Capital, Entrepreneur First, Founders Capital, Station F → Phagos
2025
SPRIM Global Investments and William Taylor Nominees → RheumaGen, Inc.
2025
INCO Ventures
invested in
Susu
in 2023
in a Series A deal